Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients

International Journal of Antimicrobial Agents
Joseph L Kuti, David P Nicolau

Abstract

Although epithelial lining fluid (ELF) is the presumed site for pulmonary infections, most antibiotic penetration studies are conducted in uninfected patients or healthy volunteers. Levofloxacin concentrations in plasma and ELF were collected from two previous studies involving 18 infected patients with acute exacerbations of chronic bronchitis and 15 uninfected elderly patients undergoing diagnostic bronchoscopy. Concentration data were population modelled using the BigNPAG algorithm, and a 5000-patient Monte Carlo simulation was conducted to simulate ELF exposure for a dosing regimen 750mg every 24h for five doses in plasma and ELF of infected versus uninfected patients. Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL). The volume of ELF was 57.2±25.0 and 14.8±9.0L in infected and uninfected patients, respectively, resulting in a lower simulated AUCELF exposure for infected patients (189.1±210.5 vs. 461.0±558.7μgh/mL). Penetration ratios for i...Continue Reading

References

Oct 21, 1998·Infectious Disease Clinics of North America·D E Nix
Aug 10, 2000·The Journal of Antimicrobial Chemotherapy·B AllegranziE Concia
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·John E ConteElisabeth Zurlinden
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Keith A RodvoldMark H Gotfried
Sep 28, 2005·Pharmacotherapy·Brian R OverholserKevin M Sowinski
Nov 11, 2005·International Journal of Antimicrobial Agents·John E ConteElisabeth Zurlinden
Aug 25, 2007·International Journal of Antimicrobial Agents·John E ConteElisabeth Zurlinden
Sep 12, 2007·Antimicrobial Agents and Chemotherapy·Sungmin Kiem, Jerome J Schentag
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Charles A PeloquinJohn L Johnson
May 20, 2009·Antimicrobial Agents and Chemotherapy·Keith A RodvoldG L Drusano
Aug 22, 2009·The Journal of Antimicrobial Chemotherapy·Jared L CrandonDavid P Nicolau
Feb 18, 2010·Computational Statistics & Data Analysis·Xiaoning WangDavid Z D'Argenio
Feb 9, 2011·Antimicrobial Agents and Chemotherapy·T P LodiseG L Drusano
May 19, 2012·Expert Opinion on Pharmacotherapy·Antoni Torres, Adamantia Liapikou
Jun 14, 2014·Clinical Pharmacology and Therapeutics·T W FeltonW W Hope
Sep 10, 2014·Advanced Drug Delivery Reviews·Amelia N Deitchman, Hartmut Derendorf

❮ Previous
Next ❯

Citations

Dec 29, 2016·Current Opinion in Infectious Diseases·Mohd H Abdul-AzizJason A Roberts
Apr 29, 2020·Antimicrobial Agents and Chemotherapy·Elizabeth A LakotaChristopher M Rubino
Oct 16, 2021·Clinical Pharmacokinetics·Emily N Drwiega, Keith A Rodvold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.